Janssen Presents Positive Long-Term Efficacy And Safety Of SYMTUZA® In Treatment-Naïve Adults With HIV-1
New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults ...
Tag: HIV-1
